Envoy Medical (COCH)
NASDAQ:COCH
Want to see COCH full AI Analyst Report?
COCH Stock Chart & Stats
$0.69
-$0.05(-3.47%)
At close: 4:00 PM EST
$0.69
-$0.05(-3.47%)
Day’s Range― - ―
52-Week Range$0.36 - $1.89
Previous CloseN/A
Volume61.49K
Average Volume (3M)394.38K
Market Cap
$48.27M
Enterprise Value-$9.69M
Total Cash (Recent Filing)$25.25M
Total Debt (Recent Filing)$889.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding76,881,110
10 Day Avg. Volume193,663
30 Day Avg. Volume394,378
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.10
Price to Sales (P/S)53.77
P/FCF Ratio-0.70
Enterprise Value/Market Cap-0.20
Enterprise Value/Revenue-41.40
Enterprise Value/Gross Profit13.33
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$2.50Price Target Upside262.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$200.00K
Bulls Say, Bears Say
Bulls Say
Proprietary Fully Implanted Cochlear ImplantEnvoy’s Acclaim is a fully implanted cochlear implant platform, a distinct product niche versus external processors. This structural differentiation can create durable clinical differentiation and higher barriers to entry for competitors, supporting long-term surgeon adoption and technology licensing potential.
Low Financial LeverageThe company’s low leverage and a positive equity base reduce interest burden and give financing flexibility, allowing focus on R&D and regulatory milestones. For a development-stage medtech company, lighter debt improves survivability through multi-quarter commercialization cycles and supports strategic fundraising options.
Expanded Equity Plans And Governance ContinuityShareholder approval to expand equity and ESPP and board continuity enables management to retain talent and issue equity for compensation or financing. This structural governance and capital-tool flexibility supports longer-term commercialization efforts and helps align employee incentives with product rollout.
Bears Say
Tiny Revenue ScaleRevenue is extremely small and gross profit is negative, indicating current unit economics do not cover direct costs. Over the medium term this challenges sustainable commercialization: until volumes improve and gross margins turn positive, the business will be dependent on external funding rather than self-sustaining cash flows.
Large Persistent Cash BurnSustained operating outflows near -$20M TTM demonstrate heavy cash consumption relative to revenue. This structural burn rate creates runway risk, forces recurring capital raises, and can divert management time to financing instead of commercialization, constraining long-term investment in sales and manufacturing scale-up.
Nasdaq Listing/compliance RiskOngoing bid-price noncompliance and reliance on Nasdaq extensions create persistent listing risk. Management may need dilutive financings or a reverse split to maintain listing, which can materially affect capital structure, investor base, and strategic planning over the coming 6–12 months and constrain long-term credibility.
Envoy Medical News
COCH FAQ
What was Envoy Medical’s price range in the past 12 months?
Envoy Medical lowest stock price was $0.36 and its highest was $1.89 in the past 12 months.
What is Envoy Medical’s market cap?
Envoy Medical’s market cap is $48.27M.
When is Envoy Medical’s upcoming earnings report date?
Envoy Medical’s upcoming earnings report date is Aug 17, 2026 which is in 63 days.
How were Envoy Medical’s earnings last quarter?
Envoy Medical released its earnings results on May 11, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.06.
Is Envoy Medical overvalued?
According to Wall Street analysts Envoy Medical’s price is currently Undervalued.
Does Envoy Medical pay dividends?
Envoy Medical does not currently pay dividends.
What is Envoy Medical’s EPS estimate?
Envoy Medical’s EPS estimate is -0.08.
How many shares outstanding does Envoy Medical have?
Envoy Medical has 76,881,110 shares outstanding.
What happened to Envoy Medical’s price movement after its last earnings report?
Envoy Medical reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -0.155%.
Which hedge fund is a major shareholder of Envoy Medical?
Currently, no hedge funds are holding shares in COCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envoy Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (262.32% Upside)
$2.50 (262.32% Upside)
Hedge Fund Trend
Decreased
By 297.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.06%
12-Months-Change
Fundamentals
Return on Equity
239.44%
Trailing 12-Months
Asset Growth
187.16%
Trailing 12-Months
Company Description
Envoy Medical
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
COCH Stock 12 Month Forecast
Average Price Target
$2.50
▲(262.32% Upside)
Technical Analysis
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
40.50% Insiders
1.27% Mutual Funds
19.26% Other Institutional Investors
37.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---